TIDMPRTC
PureTech Health PLC
26 August 2020
26 August 2020
PureTech Health plc
PureTech Founded Entity Vor Biopharma Appoints John King as Chief Commercial Officer
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to discovering,
developing and commercialising highly differentiated medicines for
devastating diseases, is pleased to note that its Founded Entity,
Vor Biopharma, today announced the appointment of John King as
chief commercial officer. Mr. King has more than 20 years of global
commercial leadership experience within biotechnology and rare
diseases. Mr. King will plan and lead global commercial operations
as Vor continues to advance its lead programme VOR33 and future
programmes that leverage its technology platform for the treatment
of cancer.
The announcement from Vor Biopharma is below:
Vor Biopharma Appoints John King as Chief Commercial Officer
CAMBRIDGE, Mass., - August 26, 2020 - Vor Biopharma , an
oncology company pioneering engineered hematopoietic stem cells
(eHSCs) for the treatment of cancer, today announced the
appointment of John King as chief commercial officer. Mr. King has
more than 20 years of global commercial leadership experience
within biotechnology and rare diseases. Mr. King will plan and lead
global commercial operations as Vor continues to advance its lead
programme VOR33 and future programmes that leverage its technology
platform.
"While cell therapies have already transformed the treatments of
many different indications, we have also witnessed complexities
related to their commercialisation," said Robert Ang, MBBS, MBA,
Vor's president and chief executive officer. "John's considerable
expertise and experience as our first dedicated commercial team
member will allow us to build our commercialisation strategy from
an early stage, to ensure that our programmes reach patients in
need and demonstrate endpoints that matter to all key
stakeholders."
"I believe Vor has a truly innovative approach that could
dramatically disrupt standard of care in leukaemias and I'm
honoured to join this dynamic and talented team," said Mr. King. "I
look forward to establishing a commercial foundation as Vor soon
begins to treat patients suffering from acute myeloid leukaemia and
in different indications as Vor develops additional
programmes."
Mr. King comes to Vor from Ra Pharma, recently acquired by UCB,
where he was the chief commercial officer. He led the organisation
in preparing for the global commercial launch of zilucoplan for
complement mediated diseases. Before joining Ra Pharma, Mr. King
was vice president, U.S. neurology business unit, at Alexion
Pharmaceuticals, where he was responsible for building and leading
the team that launched Soliris(R) (eculizumab) for generalised
myasthenia gravis. At Alexion, Mr. King also served as vice
president, head of global LAL-D franchise, and vice president, head
of global hematology franchise. Before joining Alexion in 2009, he
served in commercial roles at Wyeth Pharmaceuticals, including as
product director of Enbrel(R) (etanercept). Mr. King began his
career at Ernst & Young LLP. He obtained his BS in Business
Logistics and MBA from Pennsylvania State University.
About Vor Biopharma
Vor Biopharma aims to transform the lives of cancer patients by
pioneering engineered hematopoietic stem cell (eHSC) therapies. By
removing biologically redundant proteins from eHSCs, these cells
become inherently invulnerable to complementary targeted therapies
while tumour cells are left susceptible, thereby unleashing the
potential of targeted therapies to benefit cancer patients in
need.
Vor's platform could be used to potentially change the treatment
paradigm of both hematopoietic stem cell transplants and targeted
therapies, such as antibody drug conjugates, bispecific antibodies
and CAR-T cell treatments.
Vor is based in Cambridge, Mass. and has a broad intellectual
property base, including in-licenses from Columbia University,
where foundational work was conducted by inventor and Vor
Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.
About VOR33
Vor's lead product candidate, VOR33, consists of engineered
hematopoietic stem cells (eHSCs) that lack the protein CD33. Once
these cells are transplanted into a cancer patient, we believe that
CD33 will become a far more cancer-specific target, potentially
avoiding toxicity to the normal blood and bone marrow associated
with CD33-targeted therapies. Vor aims to improve the therapeutic
window and effectiveness of CD33-targeted therapies, thereby
potentially broadening the clinical benefit to patients suffering
from acute myeloid leukaemia.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 24 products and product candidates, including two
that have been cleared by the US Food and Drug Administration
(FDA). All of the underlying programmes and platforms that resulted
in this pipeline of product candidates were initially identified or
discovered and then advanced by the PureTech team through key
validation points based on the Company's unique insights into the
biology of the brain, immune and gut, or BIG, systems and the
interface between those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting.com stephanie@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Private
Policy.
END
NRAEAEPKAFPEEEA
(END) Dow Jones Newswires
August 26, 2020 08:02 ET (12:02 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024